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Abstract 
Recent data has suggested that disruption of the dystrophin-glycoprotein complex 
(DGC) may be involved in mediating the progression of cardiac hypertrophy and failure. 
Here we examined the regulation of DGC proteins in the hearts of adult (6 months), aged 
(30 months), and very aged (36 months) F344/N X BN rats . Compared to adult animals, 
the content of α- and β-dystroglycan were 6.93 ± 5.16% and 58.36 ± 3.64% higher, 
respectively (P < 0.05) in very aged animals. Immunoblotting and immunhistochemical 
analysis suggested that aging appeared to diminish alpha-sarcoglycan, beta-sarcoglycan 
and delta-sarcoglycan content by 13.89 ± 3.1%,15.8 ± 2.8% and 18.63 ± 3.04%, 
respectively (P < 0.05).  These alterations in the DGC occurred coincident with age-
associated alterations in cytoplasmic anti-rat IgG immunoreactivity, TUNEL positive 
nuclei, alpha-fodrin cleavage, indices of caspase-3 activation and diminished AKT 
phosphoryation (Ser 308). Taken together, these data suggest that aging alters cardiac 
DGC structure and function.  
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Chapter 1 
INTRODUCTION 
 It is estimated that by the year 2035, nearly one in four individuals will be 65 
years of age or older [1]. In the United States, cardiovascular disease e.g., atherosclerosis 
and hypertension, is the leading cause of mortality, accounting for over 40 percent of 
deaths in those aged 65 years and above [1]. The aged heart has a diminished functional 
and adaptive reserve capacity, an increased susceptibility to incur damage (e.g., as a 
result of ischemia), and a limited practical ability for repair/regeneration [2]. The 
mechanism(s) responsible for these phenotypic changes are not well understood.  
 Cardiac structure and function are remarkably similar among mammalian species, 
and the use of animal models has been extremely helpful in developing treatment 
strategies for alleviating heart disease in humans. The Fischer 344/Brown Norway F1 
hybrid rat (F344/N X BN ) is recommended for age-related studies by the National 
Institutes on Aging (NIA) as this hybrid rat lives longer and has a lower rate of 
pathological conditions than inbred rats.   Previous studies using the F344/N X BN  rat 
strain have demonstrated that aged F344/N X BN rat  hybrid animals exhibit left 
ventricular hypertrophy, dilatation, persistent arrhythmias and fibrosis of the heart [3]. 
These findings suggest that similar to most human studies, cardiac muscle in these 
animals undergo structural and functional changes with age. Similar to humans, the 
precise cellular and molecular mechanism(s) underlying these changes remain elusive. 
                    The dystrophin glycoprotein complex (DGC) is a group of tightly associated 
transmembrane and cytoskeletal proteins that forms a molecular bridge between 
dystrophin and the extracellular matrix [4]. DGC is formed by dystrophin, dystroglycan 
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complex (α- and β-DG ), sarcoglycans ( α, β, γ and δ ), sarcospan, syntrophins (α-1, β-1 
and β-2 ) and dystrobrevins. Dystrophin is absent from the muscles of patients affected 
by Duchenne muscular dystrophy (DMD) whereas the milder Becker muscular dystrophy 
(BMD) is characterized by several mutations that reduce dystrophin levels or result in the 
formation of a partially functional isoform [5]. Similar to dystrophin, the sarcoglycans 
may also be involved as mutations to the sarcoglycan genes have been shown to cause the 
limb-girdle muscular dystrophies (LGMD) [6, 7]. Recent data suggests that the disruption 
of dystrophin or dystrophin associated proteins (DAP) may also play a role in cardiac 
failure [8]. For example, cardiomyocytes lacking dystrophin are abnormally vulnerable to 
mechanical stress-induced injury, and are characterized by inappropriate calcium influx, 
aberrant cell signaling, increased oxidative stress, and alterations in contractile function 
[9]. 
 Interestingly, the aging mammalian heart exhibits many of these same 
characteristics [10-15].  Although not investigated, given the similarity between the aging 
and dystrophic heart it is possible that alterations in the DGC may be involved. Similarly, 
while the proteins of specific compartments of the DGC and their role in muscular 
dystrophies are well described, to our knowledge little is known about their regulation in 
cardiac muscle with aging. 
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PURPOSE 
 
 Our long term goal is to identify the cellular and molecular mechanisms 
underlying the age associated changes in cardiac muscle causing progressive impairment 
of cardiac function. The purpose of this study is to investigate how aging affects the DGC 
structure and function in the F344/N X BN rat heart. 
 
SPECIFIC AIMS 
 
 It is estimated that by 2053, nearly one in four individuals in the United States 
will be sixty-five years of age or older. Advancing age is associated with left ventricular 
hypertrophy, dilatation, and fibrosis of the heart with alteration in cardiac morphology 
and increased incidence of cardiac arrhythmias. Recent data has suggested that disruption 
of the dystrophin-glycoprotein complex (DGC) may be involved in mediating the 
progression of cardiac hypertrophy and failure [59]. We hypothesize that age-related 
alterations in the DGC may mediate age-associated cardiac dysfunction. To test this 
hypothesis, two specific aims will be pursued. 
 
Specific Aim #1  
To investigate how aging in the F344/N X BN rat  affects cardiac DGC structure. 
      Hypothesis: Aging in the F344/N X BN RAT  rat heart will be associated with 
alterations in DGC protein levels and localization.   
 
Specific Aim #2 
To investigate how aging in the F344/N X BN rat  affects cardiac DGC function.  
Hypothesis: Aging in the F344/N X BN RAT  rat heart will be associated with 
alterations in DGC function. 
-3- 
 
 
Chapter 2 
Review of the Literature 
 
 A review of the pertinent literature concerning the present study will be presented 
in the following chapter.  The following areas will be addressed:  1) Age associated 
alterations in cardiac muscle and 2) Structure and function of dystrophin glycoprotein 
complex.  
Age associated alterations in cardiac muscle 
 
 The aged (65+ years of age) now comprise the most rapidly growing segment of 
the United States and cardiovascular disease(CVD) is the leading cause of death in this 
population [16]. The occurrence, severity, and prognosis of CVD may reflect age-
associated changes in cardiovascular structure and function [17].  In humans, information 
as to how aging affects factors that regulate intrinsic myocardial contractility is 
incomplete, because the effectiveness of intrinsic myocardial contractility in the intact 
circulation is difficult to separate from the effects of ventricular preload and afterload or 
from autonomic modulatory influences on contractility. Nonetheless, a deficit in maximal 
intrinsic contractility of older persons might be expected on the basis of the reduced 
maximum heart rate, as the heart rate, per se, is a determinant of the myocardial 
contractile state [1]. Olivetti et al., (1991) examined the effects of aging on the human 
myocardium in 67 hearts obtained from individuals between the ages of 17-90 years who 
died from causes other than cardiovascular disease. Regression analysis of their results 
demonstrated that the aging process was characterized by a loss of  38 million and 14 
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million myocyte nuclei/yr in the left and right ventricular myocardium, respectively [18]. 
In another study Melissari et al., (1991) measured cardiac dimensions with respect to 
body weight, and the number of myocyte nuclei in the ventricle of 45 males and 22 
females (17 to 90 years old), who died from causes independent of cardiovascular 
disease. These researchers found that with aging, total heart weight increased slightly, 
while left ventricular and interventricular septum weights decreased significantly (r = 
0.44; P < 0.001). At the structural level the number of myocyte nuclei within the left 
ventricle (LV) decreased (r = 0.45; P< 0.001), whereas myocyte cell volume per nucleus 
increased (r = 0.30; P >0.05) with age [19]. Taken together these data suggested that 
advancing age is associated with increase in heart mass, and left ventricular hypertrophy 
due to an increase in the size of cardiac myocytes [18, 20].  
Gerstenblith et al., (1977) performed echocardiograms on 105 male participants in 
the NIA volunteer Longitudinal Study Program and their findings suggest that aging in 
the normal male is associated with altered left ventricular diastolic filling, increased aortic 
root diameter and LV hypertrophy but little change in contractile ability in the resting 
state [21]. Using 2-dimensional echocardiograms, Downes et al., (1989) studied the effect 
of aging on the pattern of LV diastolic filling in 11 elderly subjects (68 ± 5 years, mean ± 
standard deviation) and 15 normal young adults (31 ± 7 years) without coronary artery 
disease, systemic hypertension, LV hypertrophy or abnormality of LV systolic function.  
The data suggested that early diastolic filling is reduced in normal aged subjects, even in 
the absence of coronary artery disease and systolic dysfunction [22]. Morales et al., 
(2000) performed quantitative echocardiography in seventy-eight subjects (47 men; mean 
age, 51 years; age range, 23-87 years) without apparent cardiovascular and systemic 
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disease and revealed that advancing age is associated with changes in myocardial 
structure that are characterized by a greater echogenicity and loss in tonal organization, 
possibly due to increased collagen content within the fibers [23]. Taken together, these 
data suggest that cardiac aging in humans is characterized by alterations in left 
ventricular diastolic filling, ventricular dimensions, diastolic function and increased 
incidence of arrthymias. 
           Cardiac structure and function are remarkably similar among mammalian species, 
and the use of animal models has been extremely helpful in developing treatment 
strategies for alleviating heart disease in humans. Extending animal studies beyond young 
adult ages to very old ages may provide similar benefits to cardiovascular health of the 
growing aged population. The pathophysiology of age-related cardiac dysfunction has 
been mostly studied in human hearts at the time of transplantation while animal models 
have been found to be extremely useful for the assessment of pathological processes and 
the development of new treatments [24, 25]. The Fischer 344/Brown Norway F1 (F344/N 
X BN) rat is recommended for age-related studies by the NIA because this hybrid rat 
lives longer and has a lower rate of pathological conditions than inbred rats [4]. Age-
associated changes in cellular mechanisms of cardiac function include cardiac myocyte 
enlargement and coordinated changes in gene expression. These changes modify several 
key steps of cardiac muscle excitation-Ca+2 release-contraction relaxation coupling, 
resulting in a prolonged action potential, a prolonged cytosolic Ca+2 transient and a 
prolonged contraction and delayed relaxation [26].  Hacker et al.,(2006)  used 
echocardiographic and hemodynamic analyses to determine standard values for LV mass, 
LV wall thickness, LV chamber diameter, heart rate, LV fractional shortening, mitral 
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inflow velocity, LV relaxation time, and aortic/LV pressures in male F344/N X BN rats 
from adulthood to the very aged (n = 6 per 12-, 18-, 21-, 24-, 27-, 30-, 33-, 36-, and 39-
mo-old group). Their data suggested that aged rats had an increased LV mass-to-body 
weight ratio and deteriorated systolic function. Using histological analysis they 
demonstrated a gradual increase in fibrosis and a decrease in cardiomyocyte volume 
density with age [27].   
 More recently, Walker et al., (2006) performed two-dimensional ECHO 
measurements, two-dimensional guided M-mode, Doppler M-mode, and other recordings 
from parasternal long- and short-axis views on male F344/N X BN rats aged 6-, 30-, and 
36-month  and revealed persistent cardiac arrhythmias  in 72% (13/18) of 36-month rats, 
10% of (1/10) of 30-month rats and none in 6-month rats . Gross and microscopic studies 
revealed left ventricular (LV) dilatation, borderline to mild hypertrophy, and areas of 
fibrosis that were common in 36-mo rats, less evident in 30-mo rats, and absent in 6-mo 
rats [4]. These results suggested that advancing age in F344/N X BN rats is associated 
with declines in cardiac function (diastolic and systolic indices), LV structural changes 
(chamber dimensions, volumes, and wall thicknesses), and persistent arrhythmias. Taken 
together these data suggest that aging in the F344/N X BN rats, like humans, is associated 
with alterations in cardiac structure and function. To our knowledge, the molecular 
mechanism(s) responsible for mediating the age-associated phenotypic changes in the 
F344/N X BN rat heart have not been investigated.  
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Summary 
 Similar to humans, advancing age in the F344/N X BN rats appears to be 
associated with increase in heart mass, left ventricular hypertrophy due to an increase in 
the size of cardiac myocytes accompanied by focal increase in collagen, increased 
incidence of cardiac arrhythmias, decrease in ventricular compliance and impairements in 
systolic and diastolic function. To our knowledge,  the molecular events which may 
mediate age-associated changes in the F344/N X BN rat heart have not been investigated. 
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Structure and function of dystrophin glycoprotein complex 
 
 The identification of dystrophin [28] and the subsequent characterization of the 
dystrophin glycoprotein complex (DGC), [6, 7] was a major breAKThrough in 
understanding the molecular pathogenesis of muscular dystrophy. The DGC is a 
specialization of cardiac and skeletal muscle membrane, which has both mechanical 
stabilizing and signaling roles in mediating interactions between the cytoskeleton, 
membrane, and extracellular matrix. Known components of the DGC include dystrophin, 
sarcoglycans, dystroglycan, dystrobrevins, syntrophins, sarcospan, caveolin-3, and NO 
synthase [29].  
 The dystrophin isoform in cardiac and skeletal muscle is 427 kDa and is thought 
to function largely as a structural molecule although it is also the target of a variety of 
kinases, including calmodulin-dependent protein kinase II, [30, 31], p44 ERK1 mitogen-
activated protein kinase (MAPK) [37] p34 cdc2 kinase, [32] and casein kinase [33]. 
Dystrophin has been found to be phosphorylated both in vivo [33] and in vitro [32, 34], 
however, the physiological significance of these events has yet to be determined.  
 Assembly of the DGC is dependent on specific domains of the dystrophin protein, 
and accordingly, the DGC is absent from the sarcolemma of dystrophin deficient muscle 
[35]. Danialou et al., (2001) using normal and dystrophin deficient (mdx) mice models 
reported that cardiomyocytes lacking dystrophin are abnormally vulnerable to mechanical 
stress-induced injury, thereby resulting in a loss of sarcolemmal integrity and attendant 
contractile dysfunction [9].  Kamogawa et al., (2001) using aortic banding to induce 
cardiac hypertrophy in 12-week-old mdx and control mice and demonstrated that mdx 
mice showed increased vulnerability to acute pressure overload as characterized by 
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increased focal lesions in the left ventricular wall, damaged myocytes, increased 
inflammatory cells, and fibrosis [36]. Taken together, these results suggest that the 
primary function of dystrophin is to provide mechanical reinforcement to the sarcolemma 
[37].  
  The signaling mechanism(s) associated with the DGC function that might 
mediate cell death are not fully understood. β-dystroglycan is a transmembrane protein 
that binds to dystrophin or utrophin in the cytoplasm and to other proteins that have 
demonstrated roles in signal transduction including growth factor receptor binding 
protein 2 (Grb2) and focal adhension kinase (FAK) [38-44]. Both FAK and Grb2 
function as mediators of survival signaling in numerous cell types, often working through 
PI3K and the downstream effector of PI3K, AKT, (protein kinase B) a serine/threonine 
kinase [45]. How PI3K and AKT may function in cell death is not clear however, it is 
thought that cell adhesion to the extracellular matrix activates lipid-associated PI3K, [46, 
47] which in turn induces translocation of AKT from the cytoplasmic pool to the cell 
membrane, where it is activated by phosphorylation [48]. The PI3K/AKT pathway 
promotes survival in a wide variety of cells [48, 49].  Using a blocking antibody directed 
against α-dystroglycan, Langenbach.,et al, (2002) showed that disruption of dystroglycan 
interactions with laminin induces apoptosis in myotube cultures due to impaired signaling 
through the PI3K/AKT pathway. In the same study, a pharmacological inhibitor of  PI3K 
yielded decreased phosphorylation of AKT and its downstream effector, glycogen 
synthase kinase (GSK)-3β and induced apoptosis in muscle cell cultures. Together these 
results support a role for the PI3K/AKT pathway in the propagation of cell-survival 
signals mediated by the DGC [50]. 
-10- 
            The sarcoglycans are a family of homologous transmembrane proteins with single 
membrane spanning domains [51]. Several studies of the sarcoglycan complex have 
suggested that β- and δ-sarcoglycans are the most tightly associated and form a functional 
core of the complex [52, 53].  It is thought that the sarcoglycan complex is necessary for 
“stabilization” of the DGC in general and the dystrophin–dystroglycan interaction in 
particular [52, 53]. The association of the DGC with focal adhesion proteins such as b1-
and b3-integrins, vinculin, and FAK is modulated by α-sarcoglycan expression 
suggesting perhaps that the sarcoglycans may also be involved in cell signaling [54]. 
Further studies examining the role of the sarcoglycans and the DGC using ex vivo models 
of muscle loading and contraction will be invaluable to furthering our understanding of 
DGC function and structure.  
 
Summary 
 The dystrophin glycoprotein complex forms a strong mechanical link between the 
cytoskeleton and extracellular matrix, and several proteins of the DGC also participate in 
signaling cascades. The signal transduction cascades associated with the DGC , like those 
associated with integrins and caveolins, play important roles in cell survival signaling, 
cellular defence mechanisms, and regulation of the balance between cell survival and cell 
death. The biochemical mechanisms by which the alterations in DGC lead to cell death 
remain elusive. To our  knowledge, the regulation of DGC with advancing age has not 
been investigated. 
-11- 
 
Chapter 3 
 
Age-related DGC structure and function in 
the F344/N X BN rat heart. 
 
 
 
 
 
S. Karkarla1, K. M. Rice1, 2, D. H. Desai2, Shinichi Asano1, Anjaiah Katta1, Sriram P 
Mupparaju1, Sarath Meduru1 and E. R. Blough1,2
 
 
 
 
 
1 Department of Biological Sciences, Marshall University 
2 Department of Pharmacology, Physiology, and Toxicology, Marshall University, 
Joan C.Edwards School of Medicine 
 
 
 
 
 
 
 
 
 
Author for correspondence: 
 
 Eric Blough, Ph.D. 
 Laboratory of Molecular Physiology 
 Suite 311, Science Building 
 Department of Biological Sciences 
 1 John Marshall Drive 
 Marshall University 
 Huntington, WV  25755-1090 
 E-mail:  blough@marshall.edu  
 
 
Running Title: Aging cardiac muscle and the dystrophin complex. 
-12- 
Abstract 
It is estimated that by 2053, nearly one in four individuals in the United States will be 
sixty-five years of age or older. Advancing age in humans and in the F344/N X BN rat  is 
associated with alteration in cardiac morphology and impaired function. Recent data has 
suggested that disruption of the dystrophin-glycoprotein complex (DGC) may be 
involved in mediating the progression of cardiac hypertrophy and failure. Whether 
alterations in the DGC may mediate age-associated cardiac dysfunction is not known. 
Here we examined the regulation of DGC proteins in the hearts of adult (6 months), aged 
(30 months), and very aged (36 months) F344/N X BN rats . The dystrophin content of 
very aged hearts was 43.66 ± 7.87% lower compared to aged animals, while α-
dystroglycan and β-dystroglycan were 6.93 ± 5.16% and 58.36 ± 3.64% higher, 
respectively (P < 0.05) compared to young adult animals. Similar changes were seen in 
the sarcoglycan proteins, where aging appeared to diminish the α-sarcoglycan, β-
sarcoglycan and δ-sarcoglycan content by 13.89 ± 3.1%,15.8 ± 2.8% and 18.63 ± 3.04%, 
respectively (P < 0.05).  Immunohistochemical analysis confirmed these data and 
demonstrated qualitative differences in localization of the DGC molecules. These 
alterations in the DGC occurred coincident with age-associated increases in cytoplasmic 
anti-rat IgG immunoreactivity, TUNEL positive nuclei, the proteolytic cleavage of α-
fodrin, diminished AKT phosphoryation (Ser 308) and evidence of caspase-3 but not 
caspase-12 activity. These data suggest that the aging in the F344/N X BN rat  heart is 
associated with differences in the composition of the DGC and further, that alterations in 
the DGC may be associated with age-associated cardiac remodeling and cardiomyocyte 
death.  
-13- 
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Introduction 
 Senesecence is associated with a progressive impairment of cardiac function, 
including stroke volume, ejection fraction, and cardiac output [55]. Structural changes in 
the aging heart include cardiomyocyte cell loss and reactive hypertrophy of the remaining 
cells [56, 57].  The factors regulating these alterations are not well understood.  The 
pathophysiology of age-related cardiac dysfunction has been mostly studied in human 
hearts at the time of transplantation while animal models have been found to be 
extremely useful for the assessment of pathological processes and the development of 
new treatments [24, 25].  Using the Fischer 344 x Brown Norway F1 hybrid rat (F344/N 
X BN rat ), an aging model particularly suited for the study of age-related 
pathophysiology  [24, 25, 58]. we and others have recently demonstrated that aging in the 
F344/N X BN rats is associated with increases in heart mass, left ventricular hypertrophy, 
increased incidence of cardiac arrhythmias, decreases in ventricular compliance and 
impairments in systolic and diastolic function [27].  The precise mechanism responsible 
for these changes is unknown.   
 The dystrophin-glycoprotein complex (DGC) is thought to provide a strong 
mechanical link from the intracellular cytoskeleton to the extracellular matrix.  Known 
components of the DGC include dystrophin, dystroglycans, sarcoglycans, integrins, 
caveolin-3 and others, with the expression of these proteins differing depending on 
muscle type [59].  Recent data have suggested that disruption of the DGC may be 
involved in mediating the progression of cardiac hypertrophy and failure.  For example, 
mutation of genes encoding proteins in the DGC can cause cardiomyopathy, while the 
-14- 
disordered accumulation of DGC proteins may lead to contractile dysfunction [60, 61].  
Selective loss of dystrophin in patients with Duchenne muscular dystrophy and mdx mice 
has been shown to increase the susceptibility of cardiac myocytes to load-induced 
damage while mutations in the gene encoding dystrophin, which abolish or diminish its 
expression or which truncate the protein product, cause dilated cardiomyopathy and are 
thought to be involved in development of arrhythmias [62-65]. 
Although the proteins of specific compartments of the DGC are well described, 
little is known about their regulation in non-dystrophic muscle.  Moreover, to our 
knowledge, how aging affects the DGC in cardiomyocytes has not been investigated.  As 
aging and the dystrophies exhibit similar impacts on cardiac morphology and function, 
we hypothesized that aging would alter the expression and localization of DGC proteins 
in the cardiomyocytes.  The findings of such alterations, if present, would be important as 
this information may provide insight regarding the mechanisms underlying age-
associated cardiac dysfunction.   
 In the present study, we examined the effects of aging on the relative content of 
several proteins belonging to the DGC in the hearts of  F344/N X BN rats.  Our data 
suggest that aging alters the regulation of DGC proteins and that this regulation is similar 
to that observed during myocardial infarction.  Although it is likely that dissimilar 
mechanism(s) underlie the cardiac dysfunction seen in aging and the muscular 
dystrophies our data are consistent with the notion that both conditions are associated 
with alterations in the DGC.     
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MATERAIALS AND METHODS 
Animals   
 Animal care and procedures were conducted in accordance with the Animal Use 
Review Board of Marshall University using the criteria outlined by the American 
Association of Laboratory Animal Care as proclaimed in the Animal Welfare Act (PL89-
544, PL91-979, and PL94-279).  Adult (6 months, n=12), aged (30 months, n=12), and 
very aged (36 months, n=12) male F344/N X BN rats were obtained from the National 
Institute on Aging.  Rats were housed two per cage in an AALAC approved vivarium.  
Housing conditions consisted of a 12H:12H dark-light cycle with temperature maintained 
at 22 ± 2° C.  Animals were provided food and water ad libitum.  Rats were allowed to 
recover from shipment for at least two weeks before experimentation began.  During this 
time the animals were carefully observed and weighed weekly.  None of the animals 
exhibited signs of failure to thrive, such as precipitous weight loss, disinterest in the 
environment, or unexpected gait alterations. 
 
Materials  
Antibodies used were dystrophin (dys-2) from Novacastro (Ontario, Canda); α-
dystroglycan (VIA4-1) from Upstate (Charlottesville, VA); β –dystroglycan (sc16165),  
β –Sarcoglycan (sc 28279), δ –Sarcoglycan (sc28281) from Santa Cruz (Santa Cruz, CA); 
α-sarcoglycan (VP-A105) from Vector Laboratories (Burlingame, CA); and rat IgG  
antibody (T6392) from Molecular Probes (Eugene, OR).  Caspase 3, Caspase 9, Caspase 
12, α-fodrin, AKT, Thr308 phosphorylated AKT, BAD, Ser112 phosphorylated BAD, 
Ser136 phophorylated BAD, XIAP antibodies and Rabbit and mouse IgG secondary 
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antibodies were purchased from Cell Signaling Technology (Beverly, MA). In Situ Cell 
Death Detection Kit, Fluorescein (TUNEL) was from Roche Diagnostics (Mannheim, 
Germany).  Precast 10% SDS-PAGE gels were procured from Cambrex Biosciences 
(Baltimore, MD), and enhanced chemiluminescence (ECL) western blotting detection 
reagent was from Amersham Biosciences (Piscataway, NJ).  Restore western  blot 
stripping buffer was obtained from Pierce (Rockford, IL) 3T3 and L6 cell lysates were 
from Santa Cruz Biotechnology (Santa Cruz, CA).  All other chemicals were purchased 
from Sigma (St. Louis, MO).  
 
Determination of DGC protein content  
 Animals were anesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg ip) 
and supplemented as necessary for reflexive response [58].  Hearts were quickly 
removed, blotted dry, weighed, and immediately frozen in liquid nitrogen.  Tissues were 
stored at -80° C until use.  For the preparation of protein isolates, heart tissues were 
pulverized in liquid nitrogen using a mortar and pestle and washed three times with ice 
cold phosphate buffered saline (PBS).  Proteins were extracted by incubating samples on 
ice in 10 μl/mg of modified RIPA Buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 0.25% 
Na-deoxycholate, 1 mM EDTA, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 
1 mM PMSF, 1 mM Na3VO4, 1 mM NaF) and centrifugation for 10 min at 800 * g.  After 
removing the supernatant, pellets were re-extracted twice and then washed three times 
with ice cold PBS.  Membrane proteins were obtained by resuspending the pellets (1ml/g) 
in a buffer containing 1% deoxycholate, 1% NP-40, 10 mM NaPO4, 140 mM NaCl, and 2 
mM EDTA  supplemented with100 mM NaF, 1 mM Na3VO4, 2 mM PMSF 1 μg/ml 
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aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin.  After collecting the supernatant by 
centrifugation for 10 min 800 * g, protein concentration was determined in triplicate via 
the Bradford method (Pierce) using bovine serum albumin as a standard.  Samples were 
boiled and analyzed using 7.5% or 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE).  To allow direct comparisons to be made between age 
groups, samples from different age groups were run on the same gel.  Following 
electrophoresis, protein was transferred onto Hybond nitrocellulose membranes 
(Amersham Biosciences, Piscataway, NJ) using standard conditions [66] and stained with 
Ponceau S (data not shown) to confirm successful transfer of proteins and equal loading 
of lanes.  Membranes were blocked in tris buffered saline (TBS) with 0.5% Tween-20 
(TBS-T) and 5% milk for 1 hr at room temperature, washed (TBST, 3 * 5 min), and 
incubated in primary antibody overnight at 4ºC or 1 hr at room temperature as outlined by 
the antibody manufacturer.  After washing(TBST, 3 * 5 min), membranes were incubated 
in horseradish peroxidase (HRP)-linked secondary antibodies for 1 hr at room 
temperature, washed (TBS-T, 3 * 5 min) and the protein bands visualized by enhanced 
chemiluminescence (ECL) Western blotting detection reagent (Amersham Biosciences, 
Piscataway, NJ). Bands were quantified by densitometry (Epson Perfection 3200 PHOTO 
scanner) and Imaging software (AlphaEaseFC).    Exposure time was adjusted to keep the 
integrated optical densities within a linear and nonsaturated range.  Specificity of the 
bands was assessed using Dual Color molecular-weight markers (Pierce), a biotinylated 
protein ladder (Pierce), and NIH 3T3 or L6 cell lysates (Cell Signaling) positive controls.  
Immunoblots were stripped with Restore western blot stripping buffer as detailed by the 
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manufacturer.  After verifying the absence of residual antibody binding by interrogating 
the membrane with the ECL reagent, membranes were washed and reprobed.   
 
Histological imaging and immunohistochemistry 
 Hearts were sectioned (8 μm) using an IEC Minotome cryostat and collected on 
poly-lysine (Sigma, St. Louis, MO) coated slides.  After fixing in acetone (-20°C for 2 
min), sections were stained with hematoxylin and eosin and mounted for the evaluation 
of cardiac morphology.  Immunostaining for dystrophin, rat IgG, α-dystroglycan, β-
dystroglycan, and α-sarcoglycan was visualized by immunofluorescence as outlined by 
the antibody manufacturer.  Briefly, sections were incubated for 30 min in a blocking 
solution (5% bovine serum albumin (BSA) and PBS containing 0.5% Tween 20 (PBS-T, 
pH 7.5) and then incubated with specific antisera diluted in PSB-T (anti-dystrophin 
1:100, α-dystroglycan 1:100, β-dystroglycan 1:100, α-sarcoglycan 1:100, rat-IgG 1:100) 
for 1 hr at 37˚C in a humidified chamber.  After washing in PBST (3 * 5 min), sections 
were incubated with the appropriate FITC or Texas RED labeled secondary antibody 
(1:200) if appropriate, for 1 hr at 37˚C in a humidified chamber.  After mounting, 
specimens were visualized by epifluorescence using an Olympus fluorescence 
microscope (Melville, NY) fitted with a 40X objective or on a Nikon Diaphot microscope 
for confocal analysis.  Confocal imaging was performed using a BioRad MRC 1024 
scanning system using the 488 nm line from a krypton/argon laser for flourophore 
excitation.  Emissions were collected through either 515 nm long pass or 522/532 nm 
band pass filters.  To allow approximate quantitative comparisons, all imaging 
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parameters (pixel dwell time, optical and electronic filters, confocal iris, laser power, and 
detector gain and offset) were kept constant between samples. 
 
TUNEL Staining 
 Tissue sections (8 μm) obtained from 6- (n=3), 30- (n=3), and 36- (n=3) month 
hearts were fixed with 4% paraformaldehyde, washed with PBS (pH 7.4), and then 
permeabilized with 0.1% sodium citrate and 0.1% Triton X.  DNA fragmentation was 
determined by TdT-mediated dUTP nick end labeling (TUNEL) as suggested by the 
manufacturer’s recommendations.  Cross-sections from each muscle were treated with 
DNase I to induce DNA fragmentation as a positive control.  Three randomly selected 
regions from each cross section were visualized by epifluorescence using an Olympus 
fluorescence microscope (Melville, NY) fitted with a 20X objective.  Images were 
recorded digitally using a CCD camera (Olympus, Melville, NY), and the samples were 
analyzed by counting positively stained nuclei. 
 
Data Analysis 
Results are presented as mean ± SEM.  Data were analyzed using SigmaStat 3.5.  
A one-way analysis of variance (ANOVA) was performed for overall comparisons with 
the Student-Newman-Keuls post hoc test used to determine differences between groups.  
The level of significance accepted a priori was P≤ 0.05.  
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RESULTS 
Aging in the F344/N X BN rat  heart is associated with alterations in the cardiac 
DGC 
 Compared to young adults (6 mo), heart mass was 88.54 ± 8.38% and 72.9 ± 
6.98% higher in 30- and 36-month old animals, respectively (P < 0.05) (Table 1).  
Immunoblots of protein isolates obtained from the membrane fraction of adult, aged and 
very aged hearts were examined for the relative abundance of dystrophin as outlined 
previously [67].  Compared to 6 month animals, the amount of dystrophin was 52.9 ± 
2.49% higher (P < 0.05) and unchanged in 30- and 36-month hearts, respectively 
(Fig.1A). To assess the subcellular distribution of dystrophin, heart cross sections were 
examined by immunohistochemical analysis.  Immunoflourescent antibodies against the 
carboxy terminus of dystrophin in the 6-month heart muscles showed uniform 
immunoreactivity, predominantly along the membranes of the myocytes (Fig.1B). The 
dystrophin immunoreactivity along the membranes of very aged heart fibers appeared 
irregular with patches of intense fluorescence. With aging, the dystrophin 
immunoreactivity often appears to be discontinuous and was at times completely abscent 
along the sarcolemma of cardiac muscle fibres (Fig. 1C) of very aged hearts. Together, 
these data suggest that dystrophin content and localization are altered with aging. 
 Because alterations in the amount of dystrophin may influence the composition of 
the DGC, we examined whether aging may affect the amount of membrane associated 
dystroglycans and sarcoglycans. Immunoblot analysis showed that the amount of α-
dystroglycan was unchanged in the 30-month hearts while it was 6.93 ± 5.16%  higher in 
hearts from 36- compared to 6-month animals (P < 0.05; Fig. 2A). Immunohistochemical 
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comparisons revealed more diffuse α-dystroglycan immunoreactivity in the cytosol in the 
36-month hearts cross sections (Fig. 2B) as compared to 6-month hearts where α-
dystroglycan immunoreactivity was predominantly membrane associated (Fig. 2C). This 
suggests that aging may be associated with alterations in the amount of α-dystroglycan 
appropriately targeted to the cell membrane.  
Compared to 6-month animals, the amount of β-dystroglycan was unchanged and 
58.36 ± 3.64%, higher (P < 0.05) in 30- and 36-month hearts, respectively (Fig. 2D). 
Supporting these data, immunofluorescence findings demonstrated that the amount of 
membrane associated β-dystroglycan appeared to be altered with aging. Six-month hearts 
showed smooth and well-defined membrane, bordering each myofiber (Fig. 2E), whereas 
in 36-month hearts the β-dystroglycan immunoreactive signal was more intense and 
diffuse (Fig. 2F).  
Conversely, the content of α-sarcoglycan was found to be slightly, yet 
significantly lower in 30- (8.47 ± 2.6%) and 36-month (13.89 ± 3.1%) hearts as compared 
to 6-month hearts (Fig. 3A; P < 0.05). As opposed to the well defined immunoreactive 
signal in 6-month hearts ( Fig. 3B), with aging, the α-sarcoglycan immunohistochemical 
staining in 36-month hearts appears, microscopically, as a broad band at the sarcolemma 
with occasional whispy extensions into the proximal sarcoplasm (Fig. 3C). Similar to α–
sarcoglycan, with aging, the amount of β-sarcoglycan and δ-sarcoglycan in 30- and 36-
month hearts was significantly lower by 11.85 ± 3.35% and 15.8 ± 2.8%,  and 27.62 ± 
2.41% and 18.63 ± 3.04%, respectively, (P < 0.05; Figs. 4A, 4B). 
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 Alterations in membrane dystrophin content are associated with changes in cardiac 
myofibre membrane stability 
 Because the DGC is thought to play a pivotal role in stabilizing the muscle cell 
membrane we examined whether age-associated alterations in the DGC complex were 
associated with alterations in membrane permeability. To test this possibility, we 
examined tissue sections obtained from adult, aged and very aged rat hearts for the 
presence of IgG (150 kDa), a serum protein that is normally excluded from entry into the 
muscle fiber. No evidence of IgG immunoreactivity was demonstrated in the cytosol of 
cardiac muscle fibres obtained from 6-month rats (Fig. 5A). In contrast, with aging 
positive staining with anti-rat IgG antibodies was observed in the cytoplasm of cardiac 
myofibres obtained from 30-month (Fig. 5B) and 36-month rats (Fig. 5C).  Taken 
together, these data suggest that aging in the F344/N X BN rat  heart is associated with 
alterations in myocyte permeability.  
 
Aging in the F344/N X BN rat  heart is associated with increased TUNEL positive 
staining and casapase-3 activation 
It is well established that alterations in membrane permeability are associated 
with cellular apoptosis [68]. To examine whether age-related changes in IgG permeability 
are related to myocyte apoptosis we examined the number of nuclei staining positively 
for DNA fragmentation by TUNEL staining. Compared to 6-month hearts, the number of 
TUNEL positive nuclei increased by ~ 29 and ~ 48 fold in 30-and 36-month hearts, 
respectively (P < 0.05; Fig. 6). 
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 A critical step in the execution of the apoptotic program eliciting DNA 
fragmentation is cleavage of caspase-3 into 19- and 17- kDa fragments [69]. Caspases are 
cysteine-dependent aspartate specific proteases functioning as endonucleases integral in 
the final execution of nuclei and cell death [69, 70]. With aging the amount of the full 
length (inactive) caspase 3 was 38.26 ± 4.09% higher in the 30 month hearts, while it is 
9.69 ± 4% lower in the 36-month hearts as compared to the 6 month hearts (Fig. 7C) (P < 
0.05). Caspase-3 activation as measured by densitometric analysis of the cleaved 17 kDa 
caspase-3 fragment content, was markedly higher in the 36month hearts (138.2 ± 
34.36%) as compared to 6-month hearts, with no significant difference between the 6-
month and 30-month hearts (Fig. 7A). The content of the 19 kDa cleaved caspase-3 
fragment was 32.28 ± 2.43% and 192.4 ± 15.6% higher in the 30- and 36-month hearts as 
compared to the 6 month hearts (Fig. 7B; P < 0.05). To examine the upstream signaling 
events responsible for the activation of caspase-3, we investigated the regulation of 
caspases-9 and -12 with aging. Caspase-9 is activated via mitochondrial cytochrome C 
release and is thought to activate caspase-3, while caspase-12 signals the endoplasmic 
reticulum / sarcoplasmic reticulum (ER/SR) stress induced apoptosis [71]. The content of 
38 kDa fragment of procaspase-9 was 13.2 ± 3.36% lower in 30-month hearts and 6.45 ± 
2.68% higher in 36-month hearts compared to 6-month hearts (Fig. 8A). The 40 kDa 
fragment of caspase-9 was higher (34.83 ± 9.32) in 36-month hearts (P < 0.05) with no 
significant difference between 6-and 30-month hearts (Fig. 8B). In a similar fashion, the 
amount of full length caspase-9 was 31.23 ± 11.73% higher in 36-month hearts (P < 0.05) 
with no significant difference in 30-month hearts compared to 6-month hearts (Fig. 8C). 
No evidence of caspase-12 cleavage was detectable. 
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 As a means of further verifying the activation of caspase-3 we examined the 
effects of aging on the cleavage of α-fodrin, a cytoskeletal protein which undergoes 
caspase dependent proteolytic processing in many types of cell death [72] but has not, to 
our knowledge, been studied in aging cardiac muscle. The content of α-fodrin was (13.65 
± 1.71%) lower in 30-month hearts and unchanged in 36-month, compared to 6-month 
hearts (Fig. 9A). The full length 240 kDa α-fodrin protein can be cleaved at several sites 
within its sequence by activated calpains to yield an N-terminal fragment of 150 kDa  or 
caspases yielding a C-terminal 120 kDa product [73, 74]. Compared to hearts obtained 
from 6-month animals, the amount of the caspase dependent form of α-fodrin cleavage 
was 23.84 ± 4.3% lower (P < 0.05) in 30-month hearts and 16.52 ± 1.2% higher (P < 
0.05) in 36-month (Fig. 9B). The calpain-dependent (150kDa) fragment of α-fodrin 
cleavage was undetectable. Taken together these data suggest that aging in the F344/N X 
BN rat  heart is association with increased caspase-3 but not caspase-12 activation. 
  
The regulation of anti- and pro-apoptotic regulators with Aging in the F344/N X BN 
rat  heart is associated with alterations in AKT phosphorylation and AKT-
associated signaling  
              AKT/PKB is a serine/threonine protein kinase that functions as a critical 
regulator of cell survival and proliferation [75]. The content of AKT was 27.97 ± 2.28% 
and 14.05 ± 2.06% lower (P < 0.05) in 30-and 36-month hearts compared to 6-month 
hearts (Fig. 10A). In a similar fashion, compared to that seen in the hearts obtained from 
6-month animals, the amount of AKT phosphorylation (Thr 308) was 24.15 ± 3.2% and 
25.66 ± 2.12% lower  (P < 0.05) in the 30- and 36-month hearts, respectively (Fig. 10B). 
-25- 
Although not fully understood, it is thought that AKT may exert some of its anti-
apoptotic functions through its ability to affect the activity of other anti-apoptotic proteins 
such as BAD and X chromosome-linked inhibitor of apoptosis protein (XIAP) [76-78]. 
To further explore how age-related changes in AKT regulation and apoptosis may be 
linked we examined how aging may alter the regulation of BAD  and XIAP. Compared to 
6-month cardiac isolates, the amount of BAD in 30- and 36-month hearts was 39.08 ± 
10.99% and 40.41 ± 8.7% higher (P < 0.05; Fig. 11A). In a similar fashion, the AKT-
dependent form of phosphorylated BAD (Ser 112) was 103.73 ± 3.37% higher (P < 0.05) 
in 30- than 6-month hearts (Fig. 11B) while compared to 6-month hearts, the 
phosphorylation of BAD at Ser 136 was 74.95 ± 8.04% higher (P < 0.05) in samples 
obtained from 36-month old animals (Fig. 11C). In a similar fashion, XIAP, an 
antiapoptotic protein thought to inhibit caspase-3, was 122.86 ± 16.34% and 148.57 ± 
3.02% higher in 30-and 36-month hearts compared to 6-month hearts (Fig. 12). Taken 
together these data suggest that aging in the F344/N X BN rat  is associated with changes 
in the levels of AKT phosphorylation and AKT-associated signaling.  
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Discussion 
 Increasing age is thought to be the major risk factor for cardiovascular disease [1].  
In otherwise healthy persons and rats, the aging heart is characterized by increased left 
ventricular wall thickness and chamber diameter, increased mass and reduced diastolic 
function [57].  The cellular mechanism(s) responsible for these structural and 
physiological alterations remain largely unexplained.  Similarly, how aging may affect 
the molecular organization or function of the cardiac myocyte has remained elusive.  In 
present investigation we examined how aging may effect the protein composition of the 
DGC in the hearts of F344/N X BN rats, an animal model considered by many as 
particularly appropriate for the investigation of gerontological phenomena [79].  Our 
findings suggest that aging in the F344/N X BN heart is associated with alterations in 
DGC-related protein content and localization.  
 
The regulation of DGC proteins is altered in the aging F344/N X BN rat  heart. 
 Alterations to the muscle DGC and how these changes may influence muscle 
morphology or function have been well examined in the muscular dystrophies [80, 81].  
Similarly, it is known that the Duchenne and Becker muscular dystrophies, are associated 
with high incidence of dilated cardiomyopathy [62, 82], and that dystrophin mutations are 
a cause of X-linked dilated cardiomyopathy [64, 83], suggesting perhaps that disruption 
of the dystrophin–glycoprotein complex may be associated with cardiac dysfunction [84].   
Less understood however, is how the DGC of cardiac muscle is regulated or how aging 
may affect this complex in the absence of disease.  One of the main findings of the 
present study is that aging in the F344/N X BN rat heart appears to be associated with 
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alterations to both the dystroglycan (Fig. 2) and sarcoglycan (Fig. 3) complexes. The 
regulation of these complexes appears to occur in a diametric fashion. For example, while 
β-dystroglycan protein levels increase with aging, the amount of α-, β- and γ-sarcoglycan 
decrease. It has been hypothesized that β-dystroglycan acts as a link between proteins in 
the DGC complex and the extracellular matrix [5] as such, we feel it likely that the age-
associated upregulation of β-dystroglycan we detect may represent an adaptive response 
of cardiomyocyte to “reestablish” functional connection between the cell cytoskeleton 
and the extracellular matrix.  Further experiments using other time points within the 
aging spectrum will no doubt be useful in determining if this situation is indeed 
occurring.   
 Although the complete function of the DGC has not been determined, it is thought 
that the primary function of the DCG is to regulate the structural stability of the muscle 
cell membrane.  Indeed, in the presence of altered dystroglycan or sarcoglycan levels, it 
has been shown that the muscle membrane is destabilized [85, 86]. This destabilization of 
the membrane in turn, is associated with increased cell apoptosis [50, 87].  Our findings 
that aging in the F344/N X BN rat heart is associated with increases in membrane 
permeability (Fig. 5) and TUNEL positive cells (Fig. 6) are consistent with the possibility 
that alterations in the aging cardiac DGC are associated with membrane stability and 
increased cell apoptosis. Future studies perhaps using in vitro models will be useful at 
further substantiating this premise.  
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Alterations in DGC regulation in the aging F344/N X BN rat  heart are associated 
with increased caspase activation.  
 Remodeling of the aging heart typically involves a large net loss of active cardiac 
myocytes (≥ 30%) and reactive hypertrophy of the remaining cells [88-91]. The 
mechanism(s) which mediate these age-related decreases in myocyte number are not fully 
understood but recent data suggest that apoptosis may be involved [92, 93].  One of the 
major apoptotic signaling pathways includes the mitochondrial-driven pathway [94]. Two 
of the key effectors of the mitochondrial-mediated pathway are the endopeptidases, 
caspase-9 and caspase-3 [95, 96].  In this pathway, it is postulated that cytosolic 
cyotochrome c couples with apoptotic protease activating factor-1 (Apaf-1) which in turn, 
binds caspase-9. Auto cleavage of caspase-9 results in the formation of the complete 
‘‘apoptosome’’ (Apaf-1, adenosine triphosphate, cytochrome c) that cleaves and activates 
procaspase-3 [70]. Active caspase-3 in turn, is thought to initiate other capases resulting 
in proteolytic disassembly of the cell [96]. To examine the mechanism of age-related 
DNA strand breakage in the aging rat heart we first investigated how aging effected the 
expression and activation of caspase-3 and -9. Because caspases are normally activated 
by proteolytic cleavage [97], we examined the effects of aging on the amount of full-
length versus cleaved caspase-3 in the F344/N X BN rat  heart. With aging in the rat heart 
we found alterations in the level of cleaved caspase-3 and in the amount of its upstream 
activator, caspase-9, (Figs. 7 and 8). As a means of further investigating the possibility of 
caspase-3 activation, we used immunoblotting as a measure to determine calpain-
dependent proteolysis of α-fodrin [72].  Consistent with our caspase-3 data, with aging 
we observed a significant increase in the amount of caspase-cleaved α-fodrin (Fig. 9). 
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Taken together, these data suggest that the mitochondrial-mediated apoptosis may play a 
significant role in mediating age-related cardiac apoptosis. Similar findings with regards 
to the possibility that these caspases may be involved in cardiac remodeling during aging 
have been reported previously [92, 93].  
 Similar to the mitochondria, the endoplasmic reticulum / sarcoplasmic reticulum 
(ER/SR) may also be involved in mediating cell apoptosis. In this instance, it is thought 
that cellular stress may cause calcium influx into the cytoplasm from the extracellular 
environment and from the ER or SR through the cell membrane and the ER/SR channels, 
respectively [98]. Given the key role that the ER/SR plays in regulating cardiac calcium 
homeostasis and the synthesis of secretary proteins such as atrial natriuretic peptide in the 
heart, the possibility exists that dysfunction of the ER might thus contribute to the 
pathogenesis of heart disease [99]. Although not fully understood, it is thought that 
caspase-12 plays an important role in the process of cell death caused by ER stress [100]. 
To our knowledge, the possibility that ER/SR stress may play a role in the aging heart has 
not been investigated. With aging we failed to detect any evidence of caspase-12 
activation (Fig. 13) suggesting that SR/ER stress is not the primary cause of age-related 
apoptosis in the aging F344/N X BN rat heart.  
 
 
Alterations in DGC regulation in the aging F344/N X BN rat heart are associated 
with decreased AKT phosphorylation. 
 In addition to the caspases which are thought to be pro-apoptotic, it is possible 
that age-related changes in the heart DGC could be associated with decreases in anti-
apoptotic signaling. For example, inhibition of α-dystroglycan binding to laminin-2 has 
been found to be associated with diminished phosphorylation of protein kinase B (AKT) 
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and induction of apoptosis in muscle cell cultures [50].  In the present investigation, we 
observed that the amount of phosphorylated AKT (Thr 308) is reduced with aging (Fig. 
10).  Whether these events are due to age-associated alterations in α-dystroglycan binding 
to laminin-2 alone, or act in concert with other factors, is presently unclear. To further 
investigate the role of AKT in cardiac apoptosis, we examined the levels and activation 
of BAD. BAD is a pro-apoptotic, member of the Bcl-2 family that can displace Bax 
binding from Bcl-2 and Bcl-XL, resulting in cell death [70]. However, phosphorylation 
of BAD by AKT results in the binding of BAD to 14-3-3 proteins and the inhibition of 
BAD binding to Bcl-2 and Bcl-XL thereby promoting cell survival [101]. With aging we 
observed that the amount of BAD and phosphorylated BAD increased in the F344/N X 
BN rat hearts (Fig. 11). The exact reasons why aging in the F344/N X BN rat heart may 
be associated with increases in BAD and phosphorylated BAD protein levels are 
unknown; however given our findings that aging increases apoptosis and caspase-3 
activity, we suspect that these changes may represent a compensatory response to limit 
further cell death in the aging heart. 
 Like AKT, X-chromosome-linked inhibitor of apoptosis protein (XIAP) is also 
postulated to function in the prevention of apoptosis [102]. Here we report that aging 
increases XIAP in the aging F344/N X BN rat heart (Fig. 12). It is thought that XIAP acts 
to inhibit caspase-3 and -7 [103]. Similar to BAD, it is possible that aging in the F344/N 
X BN rat heart increases XIAP protein levels as a means to limit further cell death. 
Further experiments to test these possibilities will be useful to increase our understanding 
of the connection between age-related changes in the DGC and cardiac myocyte 
apoptosis.  
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 In summary, we show that the expression and localization of DGC proteins are 
altered with aging in F344/N X BN rat . The extent to which combined changes in tissue 
content and action of DGC participants plays a role in the heart cannot be assessed in the 
absence of extensive studies to evaluate experimental manipulation of these proteins. 
Nevertheless, in view of the known role DGC proteins play in the dystrophies, it may be 
reasonable to speculate that these changes contribute to or are the result of age-associated 
cardiac dysfunction.   
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Appendix 
Appendix A 
Table 1. Body weight, heart weight and heart weight to body weight ratio of young adult 
(6 month), aged (30 month) and very aged (36 month) F344/N X BN rat . An asterisk (*) 
designates significant differences from 6-month age group (P < 0.05). 
 
Table 1. Heart weight and body mass data 
 
 Age   
 6 months 30 months 36 months 
 
Body mass, g 
 
406 ± 16.5 
 
565 ± 40.04* 
 
500.0 ± 17.5* 
Heart mass, g 
Heart wt. / Body.wt 
0.96 ± 0.08 
 
 
0.237 ± 0.015 
1.81 ± 0.18* 
 
 
0.320 ± 0.025* 
1.66 ± 0.15* 
 
 
0.327 ± 0.021* 
    
 
(mean ± SE), * Significantly different than 6 month group (P < 0.05). 
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Figure legends 
 
Figure 1. Aging alters the expression and localization of Dystrophin.  
A. Protein isolates from the membrane content of hearts excised from adult (6 mo), aged 
(30 mo) and very aged (36 mo) rats were analyzed by immunoblotting for age related 
changes in Dystrophin protein expression. Data are presented as means ± SE.  Insets: 
representative blots for Dystrophin. (*) indicates significant difference from adult (6 
month) value (P < 0.05). (†) indicates significant difference from 30 month value (P < 
0.05). n = 5 for all groups. B,C: Immunolabeling of dystrophin in 6- (B) and 36-month 
(C) hearts. Arrows indicate irregular and broken immunoreactive signaling along the 
sarcolemma in the 36-month hearts. Bar = 25 µm. 
 
Figure 2. Aging alters the expression and localization of dystroglycan A,D: Protein 
isolates from the membrane content of hearts excised from adult (6 mo), aged (30 mo) 
and very aged (36 mo) rats were analyzed by immunoblotting for age related changes in 
α-and β-Dystroglycans protein expression. Data are presented as means ± SE.  Insets: 
representative blots for Dystrophin. (*) indicates significant difference from adult (6 
month) value (P < 0.05). (†) indicates significant difference from 30 month muscles (P < 
0.05). n = 5 for all groups. B,C: Immunolabeling of α-dystroglycan in 6- (B) and 36-
month (C) hearts. E,F: Immunolabeling of β-dystroglycan in 6- (E) and 36-month (F) 
hearts. Bar = 25 µm. 
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Figure 3.  Aging alters the expression and localization of α-Sarcoglycan.  
A. Protein isolates from the membrane content of hearts excised from adult (6 mo), aged 
(30 mo) and very aged (36 mo) rats were analyzed by immunoblotting for age related 
changes in α-Sarcoglycan protein expression. Data are presented as means ± SE.  Insets: 
representative blots for α-Sarcoglycan. (*) indicates significant difference from adult (6 
month) value (P < 0.05). n = 5 for all groups. B,C: Immunolabeling of α-Sarcoglycan in 
6- (B) and 36-month (C) hearts. Bar = 25 µm. 
 
Figure 4. Aging alters the expression and localization of β-and δ-Sarcoglycans.  
Protein isolates from the membrane content of hearts excised from adult (6 mo), aged (30 
mo) and very aged (36 mo) rats were analyzed by immunoblotting for age related 
changes in β-(A)and δ-Sarcoglycan(B) protein expression. Data are presented as means ± 
SE.  Insets: representative blots for α-Sarcoglycan. (*) indicates significant difference 
from adult (6 month) value (P < 0.05). n = 5 for all groups. 
 
Figure 5. Aging alters the membrane integrity. Loss of membrane integrity is 
indicated by intracellular staining of rat IgG in 6- (A), 30-(B) and 36-month (C) hearts.  
Note diffuse immunoreactive signaling within the cytoplasm of the 30-and 36 month 
hearts. Bar = 25 µm. 
 
-35- 
Figure 6. Aging increases the number of apoptotic nuclei.  
A. Increase in the number of apoptotic nuclei with aging in 6-,30-and 36-month hearts.  
(*) indicates significant difference from adult (6 month) value (P < 0.05). (†) indicates 
significant difference from 30 month value (P < 0.05). Representative cross sections 
showing the increases in nuclei exhibiting DNA strand breakage as determined by 
TUNEL staining in 6-(B), 30-(C)and 36-month(D) hearts. Bar = 25 µm.   
 
Figure 7. Aging alters the regulation of Caspase 3. Protein isolates from the cytosolic 
content of hearts excised from adult (6 mo), aged (30 mo) and very aged (36 mo) rats 
were analyzed by immunoblotting for age related changes in Caspase-3 protein 
expression. A. cleaved 17 kDa fragment of Caspase 3. B. cleaved 19 kDa fragment of 
Caspase 3. C. Full length Caspase 3. Data are presented as means ± SE.  Insets: 
Corresponding representative blots for Caspase-3. (*) indicates significant difference 
from adult (6 month) value (P < 0.05). (†) indicates significant difference from 30 month 
value (P < 0.05). n = 5 for all groups. 
 
Figure 8. Aging alters the regulation of Caspase 9. Protein isolates from the cytosolic 
content of hearts excised from adult (6 mo), aged (30 mo) and very aged (36 mo) rats 
were analyzed by immunoblotting for age related changes in Caspase-9 protein 
expression. A. cleaved 38 kDa fragment of Caspase 3. B. cleaved 40 kDa fragment of 
Caspase 3. C. Full length Caspase 3. Data are presented as means ± SE.  Insets: 
Corresponding representative blots for Caspase-3. (*) indicates significant difference 
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from adult (6 month) value (P < 0.05). (†) indicates significant difference from 30 month 
value (P < 0.05). n = 5 for all groups. 
 
Figure 9. Aging alters the regulation of α-fodrin content and cleavage. 
A. Full length (240 kDa) α-fodrin content in 6-,30-and 36-month hearts.  
B. Caspase dependent cleavage of α-fodrin (120 kDa). Data are presented as means ± SE.  
Insets: representative blots for α-fodrin. (*) indicates significant difference from adult  
(6 month) value (P < 0.05). (†) indicates significant difference from 30 month value (P < 
0.05). n = 5 for all groups. 
 
Figure 10. Aging alters the basal and phosphorylated levels of AKT. Membrane 
protein isolates from hearts excised from 6-, 30-and 36-month hearts were analyzed by 
immunoblotting for age-related changes in AKT (A) and p-AKT (Thr 308) (B) protein 
expression. Data are presented as means ± SE.  Insets: Representative blots for 
corresponding proteins. (*) indicates significant difference from adult (6 month) value (P 
< 0.05). (†) indicates significant difference from 30 month value (P < 0.05). n = 5 for all 
groups. 
 
Figure 11. Aging alters the basal and phosphorylated levels of signaling molecule 
BAD.  Cytosolic protein isolates from hearts excised from 6-, 30-and 36-month hearts 
were analyzed by immunoblotting for age-related changes in BAD (A), p-BAD (Ser 
112)(B) and p-BAD (Ser136) (C) protein expression. Data are presented as means ± SE.  
Insets: Representative blots for corresponding proteins. (*) indicates significant 
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difference from adult (6 month) value (P < 0.05). (†) indicates significant difference from 
30 month value (P < 0.05). n = 5 for all groups. 
 
 
Figure 12. Aging alters the expression of XIAP. Cytosolic protein isolates from hearts 
excised from 6-, 30-and 36-month hearts were analyzed by immunoblotting for age-
related changes in XIAP protein expression. Data are presented as means ± SE.  Insets: 
Representative blots for XIAP. (*) indicates significant difference from adult (6 month) 
value (P < 0.05). n = 5 for all groups. 
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Figure 1. Aging alters the regulation of dystrophin in the F344/N X BN rat  heart 
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Figure 2. Aging increases the amount of β-dystroglycan in the F344/N X BN rat  
heart 
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Figure 3. α-Sarcoglycan protein levels and localization is changed with aging 
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Figure 4. β-and δ-Sarcoglycan protein levels are diminished in the aging heart 
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Figure 5. Aging is associated with a loss of cardiac myocyte membrane integrity 
 
 
 
Figure 6. Aging increases the number of apoptotic nuclei 
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Figure 7. Aging increases the cleavage of caspase 
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Figure 8. Aging alters the regulation of caspase 9 
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Figure 9. Aging alters the regulation of α-fodrin content and cleavage 
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Figure 10. Aging in the F344/N X BN rat heart decreases the phosphorylation of 
AKT 
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Figure 11. Aging alters the amount and degree of BAD phosphorylation 
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Figure 12. Aging alters the expression of XIAP 
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Appendix B  
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 Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
 
Dystrophin in cardiac muscle 
Raw IOD values (relative percentage)  
 6 month 30 month 36 month 
%C 9.5 14.6 11.6 
%C 9.3 13.8 8.2 
%C 8.7 13.5 10.8 
%C 9.5 14.8 11.1 
%C 9.5 13.9 7.8 
%C 8.7 13.8 10.8 
    
N 6 6 6 
Mean 9.2 14.06667 10.05 
Strandard Deviation 0.394968 0.51251 1.619568 
Standard Error of the mean 0.176635 0.229202 0.724293 
    
 6 month 30 month 36 month 
Relative Expression Level 1 1.528986 1.092391 
Standard error of the mean 0.019199 0.024913 0.078727 
    
 6 month 30 month 36 month 
% RE 100 152.8986 109.2391 
SE 1.919948 2.491321 7.872747 
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Statistics 
 
One Way Analysis of Variance  
 
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.104) 
 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.001). 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
30 Control vs. 36 Control 2.867 3 6.605 <0.001 Yes  
30 Control vs. 6   Control 1.167 2 2.688 0.077 No  
6   Control vs. 36 Control 1.700 2 3.917 0.014 Yes  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
α-dystroglycan in cardiac muscle 
Raw IOD values (relative percentage)  
 6 month 30 month 36 month 
%C 9.5 14.6 11.6 
%C 9.3 13.8 8.2 
%C 8.7 13.5 10.8 
%C 9.5 14.8 11.1 
%C 9.5 13.9 7.8 
%C 8.7 13.8 10.8 
    
N 6 6 6 
Mean 9.2 14.06667 10.05 
Strandard Deviation 0.394968 0.51251 1.619568 
Standard Error of the mean 0.176635 0.229202 0.724293 
    
 6 month 30 month 36 month 
Relative Expression Level 1 1.528986 1.092391 
Standard error of the mean 0.019199 0.024913 0.078727 
    
 6 month 30 month 36 month 
% RE 100 152.8986 109.2391 
SE 1.919948 2.491321 7.872747 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.338) 
 
Equal Variance Test: Passed (P = 0.114) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.037). 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 month vs. 30 month 1.350 3 4.055 0.030 Yes  
36 month vs. 6 month 0.767 2 2.303 0.124 No  
6 month vs. 30 month 0.583 2 1.752 0.235 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
β-dystroglycan in cardiac muscle 
Raw IOD values (relative percentage)  
 6   Control 30 Control 36 Control 
%C 7.9 8.3 15.7 
%C 11.3 8.3 14.8 
%C 8.8 10.6 14.1 
%C 8.1 8.3 15.7 
%C 11.3 8.3 14.8 
%C 8.8 10.6 13.9 
    
N 6 6 6 
Mean 9.366667 9.066667 14.83333 
Strandard Deviation 1.540995 1.187715 0.763326 
Standard Error of the mean 0.689154 0.531162 0.34137 
    
 6 month 30 month 36 month 
Relative Expression Level 1 0.967972 1.58363 
Standard error of the mean 0.073575 0.056708 0.036445 
 6   Control 30 Control 36 Control 
% RE 100 96.79715 158.363 
SE 7.357517 5.670771 3.644517 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Failed (P < 0.050) 
 
The differences in the median values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = 0.003) 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparison Diff of Ranks q P < 0.05   
36 Control vs 30 Control 56.000 4.282 Yes   
36 Control vs 6   Control 52.000 5.888 Yes   
6   Control vs 30 Control 4.000 0.453 No   
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
α-Sarcoglycan in cardiac muscle 
Raw IOD values (relative percentage)  
 6   months 30 months 36 months 
%C 11.4 11.4 11 
%C 12.9 11.2 9.3 
%C 11.6 10.2 11 
%C 11.4 11.7 10.9 
%C 13.2 11.4 9.3 
%C 11.5 10 10.5 
%C    
N 6 6 6 
Mean 12 10.98333 10.33333 
Strandard Deviation 0.822192 0.705455 0.821381 
Standard Error of the mean 0.367696 0.315489 0.367333 
    
 6 month 30 month 36 month 
Relative Expression Level 1 0.915278 0.861111 
Standard error of the mean 0.030641 0.026291 0.030611 
 6   months 30 months 36 months 
% RE 100 91.52778 86.11111 
SE 3.064129 2.629075 3.061106 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.950) 
 
  
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.008). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
6   Control vs. 36 Control 1.667 3 5.201 0.006 Yes  
6   Control vs. 30 Control 1.017 2 3.173 0.041 Yes  
30 Control vs. 36 Control 0.650 2 2.028 0.172 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
β-Sarcoglycan in cardiac muscle 
Raw IOD values (relative percentage)  
 6 months 30 months 36 months 
%C 12.1 10.6 11.4 
%C 13 12 9.1 
%C 11.8 9.5 10.5 
%C 11.7 10.7 10.8 
%C 13.4 12.1 9.3 
%C 11.4 9.8 10.7 
    
N 8 8 8 
Mean 12.23333 10.78333 10.3 
Strandard Deviation 0.791623 1.083359 0.905539 
Standard Error of the mean 0.299205 0.409471 0.342261 
    
 6 month 30 month 36 month 
Relative Expression Level 1 0.881471 0.841962 
Standard error of the mean 0.024458 0.033472 0.027978 
 6 months 30 months 36 months 
% RE 100 88.14714 84.19619 
SE 2.44582 3.347176 2.797777 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.781) 
 
Equal Variance Test: Passed (P = 0.817) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.007). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
6 month vs. 36 month 1.933 3 5.067 0.007 Yes  
6 month vs. 30 month 1.450 2 3.800 0.017 Yes  
30 month vs. 36 month 0.483 2 1.267 0.385 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
δ-Sarcoglycan in cardiac muscle 
Raw IOD values (relative percentage)  
 6 months 30 months 36 months 
%C 14.6 10.3 9.3 
%C 12.6 9.7 11.2 
%C 12.4 8.5 11.5 
%C 14.3 10.4 9.4 
%C 12.6 9.7 11.2 
%C 12.4 8.5 11.6 
    
N 8 8 8 
Mean 13.15 9.516667 10.7 
Strandard Deviation 1.015382 0.84004 1.058301 
Standard Error of the mean 0.383778 0.317505 0.4 
    
 6 month 30 month 36 month 
Relative Expression Level 1 0.723701 0.813688 
Standard error of the mean 0.029185 0.024145 0.030418 
    
 6 months 30 months 36 months 
% RE 100 72.37009 81.36882 
SE 2.918465 2.414488 3.041825 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.267) 
 
Equal Variance Test: Passed (P = 0.968) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
6 month vs. 30 month 3.633 3 9.120 <0.001 Yes  
6 month vs. 36 month 2.450 2 6.150 <0.001 Yes  
36 month vs. 30 month 1.183 2 2.970 0.053 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
Caspase 3 (cleaved 17 kDa) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6 months 30 months 36 months 
%C 6.6 7.9 13.2 
%C 7.9 9.2 15.8 
%C 7.9 7.9 23.7 
%C 6.5 7.8 13 
%C 6.5 9.1 14.3 
%C 9.1 7.8 26 
    
N 6 6 6 
Mean 7.416667 8.283333 17.66667 
Strandard Deviation 1.062858 0.673548 5.699006 
Standard Error of the mean 0.475324 0.30122 2.548673 
    
 6 month 30 month 36 month 
Relative Expression Level 1 1.116854 2.382022 
Standard error of the mean 0.064089 0.040614 0.343641 
 6 months 30 months 36 months 
% RE 100 111.6854 238.2022 
SE 6.408869 4.06139 34.36413 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Failed (P = 0.016) 
 
Equal Variance Test: Passed (P = 0.052) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 months vs. 6 months 10.250 3 7.451 <0.001 Yes  
36 months vs. 30 months 9.383 2 6.821 <0.001 Yes  
30 months vs. 6 months 0.867 2 0.630 0.662 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
Caspase 3 (cleaved 19 kDa) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 
 6 months 30 months 36 months 
%C 6.8 8.5 16.1 
%C 6.8 8.5 17.8 
%C 5.9 8.5 21.2 
%C 6.2 8.9 17 
%C 6.2 8 17.9 
%C 6.2 8 21.4 
    
N 6 6 6 
Mean 6.35 8.4 18.56667 
Strandard Deviation 0.367423 0.34641 2.2151 
Standard Error of the mean 0.164317 0.154919 0.990623 
    
 6 month 30 month 36 month 
Relative Expression Level 1 1.322835 2.923885 
Standard error of the mean 0.025877 0.024397 0.156004 
 6 months 30 months 36 months 
% RE 100 132.2835 292.3885 
SE 2.587666 2.439675 15.60036 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Failed (P = 0.007) 
 
Equal Variance Test: Failed (P = 0.034) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 months vs. 6 months 12.217 3 22.814 <0.001 Yes  
36 months vs. 30 months 10.167 2 18.985 <0.001 Yes  
30 months vs. 6 months 2.050 2 3.828 0.016 Yes  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
Caspase 3 (cleaved 35 kDa) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6 months 30 months 36 months 
%C 12.1 13.1 9.2 
%C 10.8 15.4 8.2 
%C 7.5 13.7 10.1 
%C 12.1 13.1 8.7 
%C 10.7 14.8 8.4 
%C 7.7 14.1 10.4 
    
N 6 6 6 
Mean 10.15 14.03333 9.166667 
Strandard Deviation 2.06664 0.928799 0.909212 
Standard Error of the mean 0.924229 0.415371 0.406612 
 6 month 30 month 36 month 
Relative Expression Level 1 1.382594 0.90312 
Standard error of the mean 0.091057 0.040923 0.04006 
 6 months 30 months 36 months 
% RE 100 138.2594 90.31199 
SE 9.105708 4.092328 4.00603 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.250) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
30 months vs. 36 months 4.867 3 8.457 <0.001 Yes  
30 months vs. 6 months 3.883 2 6.748 <0.001 Yes  
6 months vs. 36 months 0.983 2 1.709 0.246 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
Caspase 9 (cleaved 38 kDa) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6   Control 30 Control 36 Control 
%C 12.3 9.1 11.6 
%C 10.9 9.3 11.6 
%C 10.8 11.1 13.2 
%C 12.2 9.5 11.7 
%C 11.1 9.4 11.8 
%C 10.9 10.8 12.7 
    
N 6 6 6 
Mean 11.36667 9.866667 12.1 
Strandard Deviation 0.691857 0.85479 0.681175 
Standard Error of the mean 0.309408 0.382274 0.304631 
    
 6 month 30 month 36 month 
Relative Expression Level 1 0.868035 1.064516 
Standard error of the mean 0.027221 0.033631 0.0268 
 6   Control 30 Control 36 Control 
% RE 100 86.80352 106.4516 
SE 2.722065 3.363113 2.680037 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Failed (P = <0.001) 
 
Equal Variance Test: Passed (P = 0.930) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 months vs. 30 months 2.233 3 7.325 <0.001 Yes  
36 months vs. 6 months 0.733 2 2.405 0.110 No  
6 months vs. 30 months 1.500 2 4.920 0.004 Yes  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
Caspase 9 (cleaved 40 kDa) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6 months 30 months 36 months 
%C 11.3 9 14.2 
%C 9.2 10.2 13.6 
%C 8.8 11.5 12.3 
%C 9.8 10.7 13.9 
%C 8.8 10.5 14.6 
%C 9.8 12.8 9.2 
    
N 6 6 6 
Mean 9.616667 10.78333 12.96667 
Strandard Deviation 0.938971 1.279714 2.004661 
Standard Error of the mean 0.419921 0.572305 0.896512 
    
 6 month 30 month 36 month 
Relative Expression Level 1 1.121317 1.348354 
Standard error of the mean 0.043666 0.059512 0.093225 
 6 months 30 months 36 months 
% RE 100 112.1317 134.8354 
SE 4.366592 5.951181 9.322479 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.674) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.004). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 months vs. 6 months 3.350 3 5.559 0.004 Yes  
36 months vs. 30 months 2.183 2 3.623 0.022 Yes  
30 months vs. 6 months 1.167 2 1.936 0.191 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
Caspase 9 (cleaved 51 kDa) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6   Control 30 Control 36 Control 
%C 9.4 9 12.3 
%C 12.3 10.5 14.3 
%C 7.8 11 13.4 
%C 7.7 11 14.2 
%C 11.6 10.8 14.8 
%C 9.8 12.2 7.9 
    
N 6 6 6 
Mean 9.766667 10.75 12.81667 
Strandard Deviation 1.900175 1.034891 2.562356 
Standard Error of the mean 0.849784 0.462817 1.14592 
 6 month 30 month 36 month 
Relative Expression Level 1 1.100683 1.312287 
Standard error of the mean 0.087009 0.047387 0.11733 
 6   Control 30 Control 36 Control 
% RE 100 110.0683 131.2287 
SE 8.700863 4.738745 11.73297 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.476) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.044). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 months vs. 6 months 3.050 3 3.858 0.039 Yes  
36 months vs. 30 months 2.067 2 2.614 0.084 No  
30 months vs. 6 months 0.983 2 1.244 0.393 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
Alpha-fodrin (cleaved 120 kDa) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6   Control 30 Control 36 Control 
%C 10.5 8.2 13 
%C 11.8 7.8 13.8 
%C 11.7 10.1 13.2 
%C 10.5 8.4 13.5 
%C 12.1 7.6 13.1 
%C 11.8 10 13.1 
    
N 6 6 6 
Mean 11.4 8.683333 13.28333 
Strandard Deviation 0.70993 1.096206 0.30605 
Standard Error of the mean 0.31749 0.490238 0.13687 
 6 month 30 month 36 month 
Relative Expression Level 1 0.761696 1.165205 
Standard error of the mean 0.02785 0.043003 0.012006 
 6   Control 30 Control 36 Control 
% RE 100 76.16959 116.5205 
SE 2.785001 4.300334 1.200612 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Failed (P < 0.050) 
 
The differences in the median values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = 0.007) 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparison Diff of Ranks q P < 0.05   
6   Control vs 30 Control 56.000 4.282 Yes   
6   Control vs 36 Control 40.000 4.529 Yes   
36 Control vs 30 Control 16.000 1.812 No   
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
alpha-fodrin (full length) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6   Control 30 Control 36 Control 
%C 12.5 10.6 12.1 
%C 11.5 9.6 10.7 
%C 11.6 10.5 11 
%C 12.3 10.5 12.1 
%C 11.4 9.7 10.8 
%C 11.8 10.5 10.9 
    
N 6 6 6 
Mean 11.85 10.23333 11.26667 
Strandard Deviation 0.450555 0.454606 0.653197 
Standard Error of the mean 0.201494 0.203306 0.292119 
 6 month 30 month 36 month 
Relative Expression Level 1 0.863572 0.950774 
Standard error of the mean 0.017004 0.017157 0.024651 
 6   Control 30 Control 36 Control 
% RE 100 86.35724 95.07736 
SE 1.700375 1.715663 2.465137 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.115) 
 
Equal Variance Test: Passed (P = 0.791) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
6   Control vs. 30 Control 1.617 3 7.500 <0.001 Yes  
6   Control vs. 36 Control 0.583 2 2.706 0.075 No  
36 Control vs. 30 Control 1.033 2 4.794 0.004 Yes  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
AKT in cardiac muscle 
Raw IOD values (relative percentage)  
 
 
 
 6 month 30 month 36 month 
%C 12.8 9 10.9 
%C 12.8 9.9 10.9 
%C 13 8.5 12.3 
%C 12.7 9.2 11 
%C 13.1 10.3 11 
%C 13.2 9 10.6 
    
N 6 6 6 
Mean 12.93333 9.316667 11.11667 
Strandard Deviation 0.196638 0.661564 0.598052 
Standard Error of the mean 0.087939 0.29586 0.267457 
 6 month 30 month 36 month 
Relative Expression Level 1 0.720361 0.859536 
Standard error of the mean 0.006799 0.022876 0.02068 
 6 month 30 month 36 month 
% RE 100 72.03608 85.95361 
SE 0.679944 2.28758 2.067968 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Failed (P = 0.003) 
 
Equal Variance Test: Passed (P = 0.420) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
6   Control vs. 30 Control 3.617 3 16.802 <0.001 Yes  
6   Control vs. 36 Control 1.817 2 8.440 <0.001 Yes  
36 Control vs. 30 Control 1.800 2 8.362 <0.001 Yes  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
p-AKT (Thr 308) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 
 6   Control 30 Control 36 Control 
%C 13.8 10.1 10 
%C 10.7 11 10.6 
%C 15 9.2 9.5 
%C 14.2 10.8 9.7 
%C 11.5 10.8 10.6 
%C 14.7 8.7 9 
    
N 6 6 6 
Mean 13.31667 10.1 9.9 
Strandard Deviation 1.783723 0.954987 0.632456 
Standard Error of the mean 0.797705 0.427083 0.282843 
 6 month 30 month 36 month 
Relative Expression Level 1 0.758448 0.743429 
Standard error of the mean 0.059903 0.032071 0.02124 
 6   Control 30 Control 36 Control 
% RE 100 75.84481 74.34293 
SE 5.990276 3.207132 2.123975 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.245) 
 
Equal Variance Test: Passed (P = 0.260) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
6   Control vs. 36 Control 3.417 3 6.838 <0.001 Yes  
6   Control vs. 30 Control 3.217 2 6.438 <0.001 Yes  
30 Control vs. 36 Control 0.200 2 0.400 0.781 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
BAD in cardiac muscle 
Raw IOD values (relative percentage)  
 6 months 30 months 36 months 
%C 9.6 9.8 10.4 
%C 8 14.6 12.3 
%C 8.7 12.6 13.9 
%C 10.3 9.6 10.3 
%C 7.5 14.4 12.7 
%C 8.6 12.3 14.4 
    
N 6 6 6 
Mean 8.783333 12.21667 12.33333 
Strandard Deviation 1.026483 2.158163 1.716586 
Standard Error of the mean 0.459057 0.96516 0.76768 
 6 month 30 month 36 month 
Relative Expression Level 1 1.390892 1.404175 
Standard error of the mean 0.052265 0.109885 0.087402 
 6 months 30 months 36 months 
% RE 100 139.0892 140.4175 
SE 5.226455 10.98854 8.740195 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.597) 
 
Equal Variance Test: Passed (P = 0.280) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.003). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 months vs. 6 months 3.550 3 5.119 0.007 Yes  
36 months vs. 30 months 0.117 2 0.168 0.907 No  
30 months vs. 6 months 3.433 2 4.950 0.003 Yes  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
p-BAD (Ser112) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6 months 30 months 36 months 
%C 7.2 15.1 12.2 
%C 7.6 16 12.1 
%C 8.2 15 6.6 
%C 7 14.8 12.5 
%C 7.5 16.2 11.9 
%C 8 15.6 6.7 
    
N 6 6 6 
Mean 7.583333 15.45 10.33333 
Strandard Deviation 0.457894 0.571839 2.859837 
Standard Error of the mean 0.204776 0.255734 1.278958 
 6 month 30 month 36 month 
Relative Expression Level 1 2.037363 1.362637 
Standard error of the mean 0.027003 0.033723 0.168654 
 6 months 30 months 36 months 
% RE 100 203.7363 136.2637 
SE 2.700347 3.37232 16.86538 
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Statistics 
 
 
One Way Analysis of Variance  
 
Normality Test: Failed (P < 0.050) 
 
The differences in the median values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = 0.003) 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparison Diff of Ranks q P < 0.05   
30 months vs 6 months 60.000 4.588 Yes   
30 months vs 36 months 48.000 5.435 Yes   
36 months vs 6 months 12.000 1.359 No   
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
p-BAD (Ser136) in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6 months 30 months 36 months 
%C 7.9 10.3 14.4 
%C 8.9 8.9 14.3 
%C 9.9 8 17.5 
%C 8.1 10.5 14.5 
%C 8.5 9.2 14.2 
%C 9.4 8.5 17.3 
    
N 6 6 6 
Mean 8.783333 9.233333 15.36667 
Strandard Deviation 0.770498 0.991295 1.579451 
Standard Error of the mean 0.344577 0.443321 0.706352 
 6 month 30 month 36 month 
Relative Expression Level 1 1.051233 1.749526 
Standard error of the mean 0.039231 0.050473 0.08042 
 6 months 30 months 36 months 
% RE 100 105.1233 174.9526 
SE 3.923078 5.047296 8.04196 
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Statistics 
 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.209) 
 
Equal Variance Test: Passed (P = 0.701) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 control vs. 6 control 6.583 3 13.843 <0.001 Yes  
36 control vs. 30 control 6.133 2 12.897 <0.001 Yes  
30 control vs. 6 control 0.450 2 0.946 0.514 No  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
XIAP in cardiac muscle 
Raw IOD values (relative percentage)  
 
 6 months 30 months 36 months 
%C 5.1 11.3 14.6 
%C 6.4 12.1 14.2 
%C 6.4 15.6 14.2 
%C 4.7 11.1 15.2 
%C 6.2 12.1 14.6 
%C 6.2 15.8 14.2 
    
N 6 6 6 
Mean 5.833333 13 14.5 
Strandard Deviation 0.739369 2.131666 0.394968 
Standard Error of the mean 0.330656 0.95331 0.176635 
 6 month 30 month 36 month 
Relative Expression Level 1 2.228571 2.485714 
Standard error of the mean 0.056684 0.163425 0.03028 
 6 months 30 months 36 months 
% RE 100 222.8571 248.5714 
SE 5.668387 16.34246 3.028032 
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Statistics 
 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.096) 
 
Equal Variance Test: Passed (P = 0.138) 
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P < 0.050  
36 control vs. 6 control 8.667 3 16.053 <0.001 Yes  
36 control vs. 30 control 1.500 2 2.778 0.068 No  
30 control vs. 6 control 7.167 2 13.274 <0.001 Yes  
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Chapter 4 
Conclusions 
The research findings described herein can be summarized in five major findings: 
1. Aging was found to alter the regulation of dystrophin glycoprotein complex in cardiac 
muscle. The content of dystroglycans is significantly increased with aging in F344/N X 
BN rat hearts. Conversely, aging significantly decreased the content of sarcoglycans in 
F344/N X BN rat hearts. 
2. Aging is associated with alterations in localization of dystrophin glycoprotein complex 
proteins along the sarcolemma of  F344/N X BN rat cardiomyocytes. 
3. Age-associated alterations in membrane dystrophin content are associated with changes 
in sarcolemmal stability of F344/N X BN rat cardiomyocytes.  
4. Aging in the F344/N X BN rat heart is associated with increased TUNEL positive 
staining and activation of  mitochondrial dependent caspases pathway of apoptosis. 
5. The regulation of anti- and pro-apoptotic regulators with Aging in the F344/N X BN rat 
heart is associated with alterations in AKT phosphorylation and AKT-associated 
signaling.  
 
Further directions 
             Future directions for research based on this study should focus on the 
mechanisms underlying the altered regulation and localization of dystrophin glycoprotein 
complex in cardiomyocytes with aging. 
              Recent data has suggested that disruption of the DGC may be involved in 
mediating the progression of cardiac hypertrophy and failure. A better understanding of 
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the signaling mechanisms of DGC in mediating cardiomyocyte cell death may provide 
insight in to the cardiac muscle aging. Currently aging and apoptosis of cardiac muscle 
are under investigation.  
               Additionally, investigation of the mechanical link between DGC and 
extracellular matrix through β-dystroglycan may provide better understanding of the 
cardiac muscle aging. Further elucidating the specific signaling proteins that mediate 
altered regulation of DGC and increased apoptosis with aging in cardiac muscle can help 
better pharmacological treatment of age associated cardiac dysfunction.   
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